Hinge Health, Inc. (NYSE:HNGE) reported upbeat earnings for the third quarter on Monday.
The company posted quarterly earnings of 66 cents per share which beat the analyst consensus estimate of 60 cents per share. The company reported quarterly sales of $235.000 million which beat the analyst consensus estimate of $224.561 million.
Hinge Health raised its FY2026 sales guidance from $856.000 million-$860.000 million to $879.000 million-$881.000 million.
“Our strong performance continues to reflect our ability to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs at scale,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “This focus on the triple aim, via a technology platform that scales and automates care delivery, is also resulting in a record sales season. Our client base is up almost 30% YoY for our MSK Care Program, roughly 40% for our GI Care Program since our acquisition announcement of Cylinder Health in August, and has nearly doubled for our Migraine Care Program since last quarter.”
Hinge Health shares gained 1.3% to $117.25 in pre-market trading.
These analysts made changes to their price targets on Hinge Health following earnings announcement.
- Needham analyst Ryan MacDonald maintained the stock with a Buy and raised the price target from $115 to $135.
- Stifel analyst David Grossman maintained the stock with a Buy and raised the price target from $130 to $135.
- Canaccord Genuity analyst Richard Close maintained the stock with a Buy and raised the price target from $105 to $134.
Considering buying HNGE stock? Here’s what analysts think:
Photo via Shutterstock